Oculis Holding AG (OCS) Profit After Tax (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Profit After Tax of -$36.8 million for Q1 2026, little changed year-over-year from -$36.7 million in Q1 2025, and down 25.23% quarter-over-quarter from -$29.4 million in Q4 2025.
Oculis Holding AG (OCS) Profit After Tax (2022 - 2026) Analysis & Trends
Oculis Holding AG's Profit After Tax history runs 5 years deep, the most recent figure standing at -$36.8 million for Q1 2026.
- In Q1 2026, Profit After Tax changed 0.26% year-over-year to -$36.8 million; the TTM figure through Mar 2026 stood at -$21.2 billion (up 9.53% YoY), while the FY2025 annual figure was -$119.4 million, down 22.41% from the prior year.
- Profit After Tax for Q1 2026 stood at -$36.8 million, down from -$29.4 million in the prior quarter.
- The five-year high for Profit After Tax was -$9.5 million in Q4 2022, with the low at -$23.3 billion in Q3 2024.
- The 5-year median for Profit After Tax is -$26.2 million (2025), against an average of -$2.8 billion.
- Peak annual rise in Profit After Tax reached 62.94% in 2024, while the deepest fall reached 118106.55% in 2024.
- Oculis Holding AG's Profit After Tax stood at -$9.5 million in 2022, then slumped by 47.82% to -$14.1 million in 2023, then plunged by 132.14% to -$32.7 million in 2024, then increased by 10.06% to -$29.4 million in 2025, then retreated by 25.23% to -$36.8 million in 2026.
- Business Quant data shows OCS's Profit After Tax at -$36.8 million in Q1 2026, -$29.4 million in Q4 2025, and -$21.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -12.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.61 Mn |
| Mar 31, 2026 | -36.84 Mn |
| Dec 31, 2025 | -29.42 Mn |
| Sep 30, 2025 | -21.07 Bn |
| Jun 30, 2025 | -30.65 Mn |
| Mar 31, 2025 | -36.94 Mn |
| Dec 31, 2024 | -32.71 Mn |
| Sep 30, 2024 | -23.30 Bn |
| Jun 30, 2024 | -23.04 Mn |
| Mar 31, 2024 | -18.44 Mn |
| Dec 31, 2023 | -14.09 Mn |
| Sep 30, 2023 | -19.71 Mn |
| Jun 30, 2023 | -14.32 Mn |
| Mar 31, 2023 | -49.75 Mn |
| Dec 31, 2022 | -9.53 Mn |
| Sep 30, 2022 | -10.31 Mn |
| Jun 30, 2022 | -12.82 Mn |